

## Chairs and Speakers

**Prof. Dr. Thomas Berg**, Universitätsklinikum Leipzig  
e-mail: Thomas.Berg@medizin.uni-leipzig.de

**Dr. Peter Buggisch**, Berufsverband Niedergelassener Gastroenterologen Deutschlands  
e-mail: Buggisch@ifi-medizin.de

**Dr. Markus Frick**, Verband Forschender Arzneimittelhersteller  
e-mail: m.frick@vfa.de

**Prof. Dr. Angelos Hatzakis**, University of Athens Medical School  
e-mail: AHatzak@med.uoa.gr

**Prof. Dr. Wolf Peter Hofmann**, Gastroenterologie am Bayerischen Platz, Berlin  
e-mail: gastroenterologen@berlin.de

**Dr. Dietrich Hüppe**, Gastroenterologische Gemeinschaftspraxis Herne  
e-mail: Hueppe.herne@t-online.de

**Dr. Patrick Ingiliz**, Praxis Driesener Straße, Berlin  
e-mail: Ingiliz@zibp.de

**Achim Kautz**, Deutsche Leberhilfe e. V.  
e-mail: Kautz@elpa-info.org

**Dr. Marc Lehmann**, Justizvollzugs Krankenhaus Berlin  
e-mail: Marc.Lehmann@jvk.berlin.de

**Prof. Dr. Michael P. Manns**, Deutsche Leberstiftung  
e-mail: Manns.Michael@mh-hannover.de

**Dr. Ulrich Marcus**, Robert Koch-Institut  
e-mail: MarcusU@rki.de

**Dr. Antons Mozalevskis**, WHO Europe  
e-mail: MozalevskisA@who.int

**Prof. Dr. Claus Niederau**, St. Josef Hospital, Oberhausen  
e-Mail: C.Niederau@kk-ob.de

**Ines Perea**, Bundesgesundheitsministerium  
e-mail: Ines.Perea@bmg.bund.de

**Prof. Dr. Ulrike Protzer**, Deutsches Zentrum für Infektionsforschung  
e-mail: Protzer@tum.de

**Dr. Sabine Richard**, AOK-Bundesverband  
e-mail: Sabine.Richard@bv.aok.de

**Prof. Dr. Christoph Sarrazin**, St. Josefs-Hospital, Wiesbaden  
e-mail: CSarrazin@joho.de

**Holger Wicht**, Deutsche AIDS-Hilfe  
e-mail: Holger.Wicht@dah.aidshilfe.de

**Prof. Dr. Stefan Zeuzem**, Klinikum der J. W. Goethe-Universität, Frankfurt am Main  
e-mail: Zeuzem@em.uni-frankfurt.de

**Dr. Ruth Zimmermann**, Robert Koch-Institut, Berlin  
e-mail: ZimmermannR@rki.de

Deutsche  
**Leberstiftung**  
German Liver Foundation

## Deutsche Leberstiftung / German Liver Foundation

The German Liver Foundation concerns itself with all issues relating to the liver – a vital organ.

To improve medical care for patients with liver disease, the German Liver Foundation conducts its own research projects, in addition to promoting projects in other institutions, and promotes collaboration projects.

The Foundation promotes research into the liver and related diseases. To this end, the foundation offers grants for research networking as well as for the preparation of clinical studies and other projects. Every year, an outstanding publication in the field of hepatology is honoured with the 'Prize of the German Liver Foundation'. In addition, the foundation makes its contacts and scientific expertise available for use.

The German Liver Foundation provides information about the liver and liver diseases through various publications. On its website [www.deutsche-leberstiftung.de](http://www.deutsche-leberstiftung.de), the foundation offers extensive information about the liver and liver disease.

Creating public awareness is an important part of German Liver Foundation's role in providing information about the liver and liver diseases. It is vital to raise awareness of the different types of liver diseases and diagnosis to improve early detection.

[www.deutsche-leberstiftung.de](http://www.deutsche-leberstiftung.de)  
[www.german-liverfoundation.com](http://www.german-liverfoundation.com)

## Directions



Kaiserin-Friedrich-Haus  
Robert-Koch-Platz 7,  
10115 Berlin  
Germany

**Organizer**  
Deutsche Leberstiftung  
(German Liver Foundation)  
Carl-Neuberg-Straße 1  
30625 Hannover  
Germany

Deutsche  
**Leberstiftung**  
German Liver Foundation

In cooperation with:



Deutsche  
**Leberstiftung**  
German Liver Foundation

**Strategietreffen** Virushepatitis  
in Deutschland eliminieren

Elimination of Viral Hepatitis in  
Europe: **the German strategy**

November 30, 2016

## PROGRAM

Dear ladies and gentlemen,  
dear colleagues,

Over the last few years there has hardly been any other development in medicine as revolutionary as the hepatitis B and C therapies. The newly developed drugs allow to control or even cure chronic infections. Preventing the progression of liver diseases such as liver cirrhosis or liver cancer can save many lives!

However, we have to meet the challenge to provide every patient with an effective therapy and to discuss critically the economic consequences of those therapeutic innovations.

The question arises how to implement those new potentials in Germany. Therefore, the Deutsche Leberstiftung (German Liver Foundation) organizes the conference: 'Elimination of Viral Hepatitis in Europe: the German strategy' in cooperation with the international 'Hepatitis B & C Public Policy Association' and the 'Deutsche Leberhilfe'.

Other European countries have already developed national strategic plans aiming at the elimination of viral hepatitis. In Germany, formally every patient has access to appropriate therapies. Due to the lack of coordinated actions and activities an effective strategy remains to be installed.

During our strategy conference we will learn from European models, analyze the present situation in Germany, and discuss with all participants possible strategies how to realize an elimination plan for viral hepatitis in Germany.

We are looking forward to your participation and contribution!



Prof. Dr. Michael P. Manns  
Chairman Deutsche Leberstiftung  
(German Liver Foundation)

## Program

### 13:00 Welcome and Presentation of the Deutsche Leberstiftung (German Liver Foundation)

Michael P. Manns

### 13:15 The European perspective

Chairs: Angelos Hatzakis,  
Michael P. Manns

#### Viral hepatitis: a European problem and the way forward

Antons Mozalevskis

#### Strategies to eliminate viral hepatitis in Europe

Angelos Hatzakis

#### Discussion

### 14:00 The current situation in Germany

Chair: Stefan Zeuzem

#### Epidemiology of viral hepatitis in Germany

Ruth Zimmermann

#### HCV in high risk populations

Ulrich Marcus

#### Treatment of HCV by specialists in private practice

Peter Buggisch

#### Natural history of viral hepatitis in Germany

Michael P. Manns

#### Discussion

### 15:00 Break

### 15:45 Strategies to eradicate viral hepatitis in Germany

Chairs: Ulrike Protzer, Holger Wicht

#### What is the minimal clinical and virological work-up required?

Christoph Sarrazin

#### The medical options: viral hepatitis can be cured or controlled in all patients

Thomas Berg

#### Important elements of an elimination strategy from the patient's perspective

Achim Kautz

#### How to target high risk populations

Patrick Ingiliz

#### Barriers to treat viral hepatitis in German prisons

Marc Lehmann

#### Discussion

### 17:00 Access to therapy

Chairs: Dietrich Hüppe,  
Claus Niederau

#### Access to therapy – the perspective of the prescriber

Wolf Peter Hofmann

#### Access to therapy – the perspective of the pharmaceutical industry

Markus Frick

#### Access to therapy – the perspective of the payers

Sabine Richard

#### Panel discussion

Moderation: Angelos Hatzakis,  
Michael P. Manns;

Markus Frick,  
Wolf Peter Hofmann,  
Antons Mozalevskis,  
Ines Perea,  
Sabine Richard

### 18:00 Concluding remarks and farewell

Michael P. Manns

The attendance of the meeting is free of charge.  
A registration is necessary.

The number of participants is limited, registrations will  
be handled on a 'first come, first served' basis.  
Therefore, we highly recommend an early registration.